Zimmer Biomet Holdings, Inc. (BVMF:Z1BH34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 91.93B -13.0% |
| Revenue (ttm) | 44.08B +8.6% |
| Net Income | 4.18B -2.0% |
| EPS | 21.33 +0.2% |
| Shares Out | n/a |
| PE Ratio | 22.00 |
| Forward PE | 10.78 |
| Dividend | 0.80 (0.65%) |
| Ex-Dividend Date | Sep 29, 2026 |
| Volume | 1 |
| Open | 122.28 |
| Previous Close | 125.28 |
| Day's Range | 122.28 - 122.28 |
| 52-Week Range | 111.66 - 129.09 |
| Beta | 0.47 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well a... [Read more]
Financial Performance
In 2025, Zimmer Biomet Holdings's revenue was $8.23 billion, an increase of 7.20% compared to the previous year's $7.68 billion. Earnings were $705.10 million, a decrease of -21.98%.
Financial numbers in USD Financial StatementsNews
Zimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
Gary Campbell promoted to President, Americas Brian Hatcher promoted to President, Recon, S.E.T., CMFT, Neuro and Biosurgery Bradley Kessler promoted to President, Americas – Robotics, Technology and ...
Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026
WARSAW, Ind., Aug. 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment o...
Zimmer Biomet Holdings Earnings Call Transcript: Q2 2026
Q2 sales grew 4.8% reported and 4% organically, led by strong U.S. hip and technology growth. Guidance for full-year organic revenue and adjusted EPS was raised, with robust cash flow and continued investments in innovation, Salesforce transformation, and M&A.
Zimmer Biomet Holdings Earnings release: Q2 2026
Zimmer Biomet Holdings released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Zimmer Biomet Holdings Quarterly report: Q2 2026
Zimmer Biomet Holdings has published its Q2 2026 quarterly earnings report on August 5, 2026.
Zimmer Biomet Announces Second Quarter 2026 Financial Results
Second quarter net sales of $2.177 billion increased 4.8% on a reported basis, 4.7% on a constant currency1 basis and 4.0% on an organic constant currency1 basis Second quarter diluted earnings per sh...
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
WARSAW, Ind., July 14, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Chintan Desai has been named president of the com...
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
WARSAW, Ind., July 13, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its second quarter earnings conference call will be we...
Medical device maker Zimmer Biomet to hire 500 in 3 years for tech centre in India
Medical device maker Zimmer Biomet plans to hire 500 employees over the next three years for its newly opened technology centre in Bengaluru, a senior executive said, as the U.S.-listed company expa...
Zimmer Biomet Holdings Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
A major U.S. sales channel overhaul is underway, aiming for full transition by end-2027 and improved productivity. Recent product launches and acquisitions are driving growth, while innovation and robotics remain key priorities. Financially, 2026 is a transition year, with mid-single-digit growth targeted beyond.
Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
WARSAW, Ind., June 2, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will ...
Zimmer Biomet Announces Quarterly Dividend for Second Quarter of 2026
WARSAW, Ind., May 22, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of...
Zimmer Biomet Holdings Transcript: AGM 2026
The meeting highlighted ongoing transformation, strategic focus on innovation, and operational excellence. Shareholders approved all board proposals except the independent chairman request, while management emphasized capital return, U.S. sales improvement, and S.E.T. growth.
Zimmer Biomet Holdings Transcript: Bank of America Global Healthcare Conference 2026
Q1 2026 delivered strong revenue growth at the top of guidance, with robust U.S. and technology performance. New product launches, especially in Japan, and ongoing sales force transformation are driving future growth. Integration of recent acquisitions and a $1B buyback support a balanced capital strategy.
Zimmer Biomet Increases Share Repurchase Expectations -- Up to $1 Billion by Year End
WARSAW, Ind., May 12, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it now anticipates repurchasing up to $1 billion o...
Zimmer Biomet to Present at the BofA Securities 2026 Health Care Conference
WARSAW, Ind., May 6, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will p...
Zimmer Biomet Holdings Earnings Call Transcript: Q1 2026
Sales and EPS exceeded expectations, driven by strong technology adoption and new product launches, with guidance for EPS and free cash flow raised for 2026. Strategic investments and sales force transformation are progressing, while recent acquisitions accelerate growth.
Zimmer Biomet Holdings Earnings release: Q1 2026
Zimmer Biomet Holdings released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Zimmer Biomet Holdings Quarterly report: Q1 2026
Zimmer Biomet Holdings has published its Q1 2026 quarterly earnings report on April 28, 2026.
Medical device maker Zimmer Biomet raises annual profit forecast, announces CFO departure
Zimmer Biomet on Tuesday raised its 2026 adjusted profit forecast after reporting better-than-expected quarterly results, helped by strong demand for its medical devices and new product launches.
Zimmer Biomet Announces First Quarter 2026 Financial Results
First quarter net sales of $2.087 billion increased 9.3% on a reported basis, 6.8% on a constant currency1 basis and 2.9% on an organic constant currency1 basis First quarter diluted earnings per shar...
Zimmer Biomet Announces Chief Financial Officer Transition
Suketu Upadhyay to Depart; Paul Stellato Named Interim CFO WARSAW, Ind., April 28, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today anno...
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results
WARSAW, Ind., April 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced its first quarter earnings conference call will be web...
Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
Experienced orthopedic surgeon from the Hospital for Special Surgery, innovator and former Chief Medical Technology Advisor joins company in an elevated capacity WARSAW, Ind., April 7, 2026 /PRNewswir...
Zimmer Biomet Holdings Proxy statement: Proxy filing
Zimmer Biomet Holdings filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.